Translating Innovative Ideas Into

IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity. IDEAYA, headquartered in South San Francisco, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology, immunology, and small molecule drug discovery.

Company OverviewRecent News

IDEAYA was founded with the premise that attracting the industry's best scientists and focusing on areas of transformative research is a proven model for delivering game-changing medicines to patients. Our people are passionate and proven cancer biologists, immunologists, and drug discovery chemists. As an organization, we believe that our entrepreneurial spirit and nimbleness, and commitment to foster innovation, teamwork and excellence is what sets us apart. Our greatest asset is our scientists and their passion to discover innovative new therapies for cancer patients.

Yujiro S. HataIDEAYA Chief Executive Officer

Synthetic Lethality

Synthetic lethality was first suggested as a potential cancer treatment modality nearly 20 years ago and proof of concept for the approach now exists with the 2014 approval of a PARP inhibitor. IDEAYA is prosecuting a novel set of DNA repair-based drug targets through a unique, tripartite approach.

Learn More


Immuno-Oncology (IO) has revolutionized our ability to treat cancer. IDEAYA’s IO programs are designed to overcome the genetic and environmental factors in the tumor microenvironment (TME) that drive cancer cell evasion from both innate and adaptive immune cells.

Learn More